First human trial tests promising new pill for Tough-to-Treat cancers

NCT ID NCT04192344

Summary

This is an early-stage study to test the safety and determine the best dose of a new oral medication called ABSK021 in people with advanced solid tumors that have stopped responding to standard treatments. The trial will enroll about 276 participants, including those with a rare joint tumor called tenosynovial giant cell tumor (TGCT). Researchers will monitor for side effects and look for early signs that the drug might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Jishuitan Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact

    Contact

  • Hebei Medical University Third Hospital

    COMPLETED

    Shijiazhuang, Hebei, China

  • Henan Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Zhengzhou, Henan, China

  • Huashan Hospital of Fudan University

    COMPLETED

    Shanghai, Shanghai Municipality, China

  • Jiangsu Province Hospital

    ACTIVE_NOT_RECRUITING

    Nanjing, Jiangsu, China

  • Liaoning Cancer Hospital

    COMPLETED

    Shenyang, Liaoning, China

  • MD Anderson Cancer Center

    COMPLETED

    Houston, Texas, 77030, United States

  • Nanjing Drum Tower Hospital

    ACTIVE_NOT_RECRUITING

    Nanjing, Jiangsu, China

  • Precision NextGen Oncology

    ACTIVE_NOT_RECRUITING

    Beverly Hills, California, 90212, United States

  • SCRI at HealthOne

    COMPLETED

    Denver, Colorado, 80218-1238, United States

  • Shanghai Sixth People's Hospital

    COMPLETED

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangdong, Guangzhou, China

    Contact

    Contact

  • The First Affiliated Hospital of Zhengzhou Universtity

    COMPLETED

    Zhengzhou, Henan, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact

    Contact

  • The Winship Cancer Institute of Emory University

    COMPLETED

    Atlanta, Georgia, 30322, United States

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, China

    Contact

    Contact

  • Xi'an Hong Hui Hospital

    RECRUITING

    Xian, Shanxi, China

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.